Harpoon Therapeutics (Harpoon Therapeutics) 3-Year Revenue Growth Rate : 53.60% (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics 3-Year Revenue Growth Rate?

Harpoon Therapeutics's Revenue per Share for the three months ended in Sep. 2023 was $1.13.

During the past 12 months, Harpoon Therapeutics's average Revenue per Share Growth Rate was 2.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 53.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 65.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 7 years, the highest 3-Year average Revenue per Share Growth Rate of Harpoon Therapeutics was 110.30% per year. The lowest was 53.60% per year. And the median was 54.50% per year.

Competitive Comparison of Harpoon Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Harpoon Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harpoon Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's 3-Year Revenue Growth Rate falls into.

Harpoon Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Harpoon Therapeutics (NAS:HARP) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Harpoon Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

5HTA:Germany

Address

131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.harpoontx.com

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

Executives

Vijay K Lathi	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker	officer: Chief Medical Officer	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza	officer: Principal Fin. & Acctng Ofc.	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail	director	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez	officer: Chief Financial Officer	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick	director	C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p.	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt	director, 10 percent owner	C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p.	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170